Apixaban trough concentrations in atrial fibrillation patients with reduced renal function
The standard dosing regimen of 5 mg apixaban BID renders exposure that is roughly twice as high in patients with moderately reduced renal function compared to patients with normal renal function. We suggest that patients with moderately reduced renal function ought to be monitored. Possibly, a dose reduction may be considered to achieve similar exposure as in patients with normal renal function.
Authors
- Jonas Fyrestam (ORCID: https://orcid.org/0000-0002-5759-4861)
- Fadiea Al-Aieshy (ORCID: https://orcid.org/0009-0000-9977-4388)
- Mika Skeppholm
- Anton Pohanka (ORCID: https://orcid.org/0000-0001-9755-0778)
- Rickard E. Malmström (ORCID: https://orcid.org/0000-0003-3061-7629)
- Fredrik Johansson (ORCID: https://orcid.org/0009-0007-3909-7160)
Institutions
- Karolinska University Hospital (SE)
- Karolinska Institutet (SE)
Publication Details
- Journal
- Biomedicine & Pharmacotherapy
- Published
- 2024-10-28
- DOI
- https://doi.org/10.1016/j.biopha.2024.117613
- Citations
- 2
- Primary Topic
- Atrial Fibrillation Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.80
Funders
- Hjärt-Lungfonden
- Stockholms Läns Landsting
- Svenska Läkaresällskapet
- Stiftelsen Stig och Gunborg Westman